NASDAQ:PMD

Psychemedics Stock Forecast, Price & News

$7.36
+0.13 (+1.80 %)
(As of 07/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.25
$7.57
50-Day Range
$6.55
$8.25
52-Week Range
$3.58
$8.36
Volume61,962 shs
Average Volume30,141 shs
Market Capitalization$40.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.79
30 days | 90 days | 365 days | Advanced Chart
Receive PMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Psychemedics and its competitors with MarketBeat's FREE daily newsletter.


Psychemedics logo

About Psychemedics

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.09 out of 5 stars

Medical Sector

1480th out of 2,218 stocks

Medical Laboratories Industry

30th out of 41 stocks

Analyst Opinion: 0.0Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Psychemedics (NASDAQ:PMD) Frequently Asked Questions

What stocks does MarketBeat like better than Psychemedics?

Wall Street analysts have given Psychemedics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Psychemedics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Psychemedics' next earnings date?

Psychemedics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Psychemedics
.

How were Psychemedics' earnings last quarter?

Psychemedics Co. (NASDAQ:PMD) announced its quarterly earnings results on Monday, May, 10th. The company reported $0.01 EPS for the quarter. The firm earned $5.71 million during the quarter. Psychemedics had a negative net margin of 18.51% and a negative trailing twelve-month return on equity of 27.72%.
View Psychemedics' earnings history
.

How has Psychemedics' stock been impacted by Coronavirus?

Psychemedics' stock was trading at $6.95 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PMD stock has increased by 6.0% and is now trading at $7.3650.
View which stocks have been most impacted by COVID-19
.

Who are Psychemedics' key executives?

Psychemedics' management team includes the following people:
  • Raymond C. Kubacki, Chairman, President & Chief Executive Officer
  • Charles M. Doucot, Executive Vice President
  • Sarah E. Ashby, Vice President & General Counsel
  • Andrew Limbek, Vice President & Controller
  • Michael I. Schaffer, Vice President-Laboratory Operations

What is Raymond C. Kubacki Jr.'s approval rating as Psychemedics' CEO?

6 employees have rated Psychemedics CEO Raymond C. Kubacki Jr. on Glassdoor.com. Raymond C. Kubacki Jr. has an approval rating of 67% among Psychemedics' employees.

Who are some of Psychemedics' key competitors?

What other stocks do shareholders of Psychemedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Psychemedics investors own include Zynerba Pharmaceuticals (ZYNE), Dominion Energy (D), Sorrento Therapeutics (SRNE), AT&T (T), AbbVie (ABBV), (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pattern Energy Group (PEGI) and Simon Property Group (SPG).

What is Psychemedics' stock symbol?

Psychemedics trades on the NASDAQ under the ticker symbol "PMD."

How do I buy shares of Psychemedics?

Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Psychemedics' stock price today?

One share of PMD stock can currently be purchased for approximately $7.37.

How much money does Psychemedics make?

Psychemedics has a market capitalization of $40.77 million and generates $21.36 million in revenue each year.

How many employees does Psychemedics have?

Psychemedics employs 138 workers across the globe.

What is Psychemedics' official website?

The official website for Psychemedics is www.psychemedics.com.

Where are Psychemedics' headquarters?

Psychemedics is headquartered at 289 GREAT ROAD Suite 200, ACTON MA, 01720.

How can I contact Psychemedics?

Psychemedics' mailing address is 289 GREAT ROAD Suite 200, ACTON MA, 01720. The company can be reached via phone at (978) 206-8220.


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.